Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth

This article was originally published in PharmAsia News

Executive Summary

Having endured one major patent expiry in the past year and facing several others in the near future, AstraZeneca has turned in a number of directions to offset potential losses from big sellers like Pulmicort Respules, Nexium, Seroquel, andArimidex, often with mixed results

You may also be interested in...



AstraZeneca Outlines Branded Generics Strategy at Emerging Markets Event

AZ's emerging markets strategy includes selective entry into branded generics

AZ Taps India's Torrent to Add Branded Generics in Emerging Markets

Innovation-only AstraZeneca gets the branded generics religion, at least in emerging markets.

AZ Continues To Buy Pipeline With $100M Rigel Deal

Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.

Related Content

UsernamePublicRestriction

Register

SC074676

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel